CSI Market
Sign In | Register

Monte Rosa Therapeutics Inc (GLUE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access GLUE Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Monte Rosa Therapeutics Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-44.50
Depreciation & amortization2.03
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-4.21
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation5.95
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Defined Benefit Plan Other Changes0.05
Noncash Lease Expense-
Accretion Of Discounts Premiums On Marketable Securities Net-0.99
Receivable From Collaboration Agreement-
Increase Decrease In Collaboration Receivable7.00
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables-0.01
Increase (Decrease) in Accounts Payable4.38
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-3.71
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.92
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.43
Discontinued operations0.00
Net Cash flow from Operating Activities-37.37
Investing Activities
Capital Expenditures-1.87
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities-332.00
Real Estate Investments0.00
Proceedsfrommaturityofmarketablesecurities72.87
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-261.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.52
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-139.78
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents134.84
Payment Of Common Stock Issuance Cost-
Restricted Cash4.95
Payment To Pre Funded Warrant Issuance Costs-
Proceeds From Underwritten Public Offering Cost-
Proceeds From Employee Stocks Purchase Plan-
Proceeds From Underwritten Public Offering324.30
Payment Of Offering Costs-0.49
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities328.34
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-39.24
Total Cash Flow29.97
4 historic quarters locked

Sign in to unlock the full Monte Rosa Therapeutics Inc cash flow history.

Sign In Create Free Account

About Monte Rosa Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-336711

Figures are derived from filed reports and may be restated. Historical data is subject to revision.